Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Catharina Schreiber is active.

Publication


Featured researches published by Catharina Schreiber.


Circulation-cardiovascular Imaging | 2013

Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction

Julia Mascherbauer; Beatrice A. Marzluf; Caroline Tufaro; Stefan Pfaffenberger; Alexandra Graf; Paul Wexberg; Adelheid Panzenböck; Johannes Jakowitsch; Christine Bangert; Daniela Laimer; Catharina Schreiber; Gültekin Karakus; Martin Hülsmann; Richard Pacher; Irene M. Lang; Gerald Maurer; Diana Bonderman

Background—The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role. Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis. Methods and Results—Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study. Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline. Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event. Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98–0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03–1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00–1.01; P=0.03) were significantly associated with cardiac events. Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01). Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01). T1 time also correlated with right ventricular–pulmonary arterial coupling (pulmonary vascular resistance: R=−0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01). Conclusions—In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.


Acta Biomaterialia | 2013

Healing characteristics of electrospun polyurethane grafts with various porosities.

Helga Bergmeister; Catharina Schreiber; Christian Grasl; Ingrid Walter; Roberto Plasenzotti; Martin Stoiber; David Bernhard; Heinrich Schima

Pore size and porosity control the rate and depth of cellular migration in electrospun vascular fabrics and thus have a strong impact on long-term graft success. In this study we investigated the effect of graft porosity on cell migration in vitro and in vivo. Polyurethane (PU) grafts were fabricated by electrospinning as fine-mesh, low-porosity grafts (void fraction (VF) 53%) and coarse-mesh, high-porosity grafts (VF 80%). The fabricated grafts were evaluated in vitro for endothelial cell attachment and proliferation. Prostheses were investigated in a rat model for either 7 days, 1, 3 or 6 months (n=7 per time point) and analyzed after retrieval by biomechanical analysis and various histological techniques. Cell migration was calculated by computer-assisted morphometry. In vitro, fine-pore mesh favored early cell attachment. In vivo, coarse mesh grafts revealed significantly higher cell populations at all time points in all areas of the conduit wall. Biomechanical tests indicated sufficient compliance, tensile and suture retention strength before and after implantation. Increased porosity improves host cell ingrowth and survival in electrospun conduits. These conduits show successful natural host vessel reconstitution without limitation of biomechanical properties.


Acta Biomaterialia | 2015

Biodegradable, thermoplastic polyurethane grafts for small diameter vascular replacements

Helga Bergmeister; Nargiz Seyidova; Catharina Schreiber; Magdalena Strobl; Christian Grasl; Ingrid Walter; Barbara Messner; Stefan Baudis; Sophie M. Fröhlich; Martina Marchetti-Deschmann; Markus Griesser; Matt di Franco; Martin Krssak; Robert Liska; Heinrich Schima

Biodegradable vascular grafts with sufficient in vivo performance would be more advantageous than permanent non-degradable prostheses. These constructs would be continuously replaced by host tissue, leading to an endogenous functional implant which would adapt to the need of the patient and exhibit only limited risk of microbiological graft contamination. Adequate biomechanical strength and a wall structure which promotes rapid host remodeling are prerequisites for biodegradable approaches. Current approaches often reveal limited tensile strength and therefore require thicker or reinforced graft walls. In this study we investigated the in vitro and in vivo biocompatibility of thin host-vessel-matched grafts (n=34) formed from hard-block biodegradable thermoplastic polyurethane (TPU). Expanded polytetrafluoroethylene (ePTFE) conduits (n=34) served as control grafts. Grafts were analyzed by various techniques after retrieval at different time points (1 week; 1, 6, 12 months). TPU grafts showed significantly increased endothelial cell proliferation in vitro (P<0.001). Population by host cells increased significantly in the TPU conduits within 1 month of implantation (P=0.01). After long-term implantation, TPU implants showed 100% patency (ePTFE: 93%) with no signs of aneurysmal dilatation. Substantial remodeling of the degradable grafts was observed but varied between subjects. Intimal hyperplasia was limited to ePTFE conduits (29%). Thin-walled TPU grafts offer a new and desirable form of biodegradable vascular implant. Degradable grafts showed equivalent long-term performance characteristics compared to the clinically used, non-degradable material with improvements in intimal hyperplasia and ingrowth of host cells.


Artificial Organs | 2012

Electrospun Small‐Diameter Polyurethane Vascular Grafts: Ingrowth and Differentiation of Vascular‐Specific Host Cells

Helga Bergmeister; Christian Grasl; Ingrid Walter; Roberto Plasenzotti; Martin Stoiber; Catharina Schreiber; Udo Losert; Guenter Weigel; Heinrich Schima

No small-diameter synthetic graft has yet shown comparable performance to autologous vessels. Synthetic conduits fail due to their inherent surface thrombogenicity and the development of intimal hyperplasia. In addressing these shortcomings, electrospinning offers an interesting alternative to other nanostructured, cardiovascular substitutes because of the close match of electrospun materials to the biomechanical and structural properties of native vessels. In this study, we investigated the in vivo behavior of electrospun, small-diameter conduits in a rat model. Vascular grafts composed of polyurethane were fabricated by electrospinning. Prostheses were implanted into the abdominal aorta in 40 rats for either 7 days, 4 weeks, 3 months, or 6 months. Retrieved specimens were evaluated by histology, immunohistochemical staining, confocal laser scanning microscopy, and scanning electron microscopy. At all time points, we found no evidence of foreign body reaction or graft degradation. The overall patency rate of the intravascular implants was 95%. Within 7 days, grafts revealed ingrowth of host cells. CD34+ cells increased significantly from 7 days up to 6 months of implantation (P < 0.05). Myofibroblasts and myocytes showed increasing cell numbers up to 3 months (P < 0.05). Ki67 staining indicated unaltered cell proliferation during the whole follow-up period. Besides biomechanical benefits, electrospun polyurethane grafts exhibit excellent biocompatibility in vivo. Cell immigration and differentiation seems to be promoted by the nanostructured artificial matrix.


Pulmonary circulation | 2017

Combined oral administration of L-arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension

Catharina Schreiber; Magdalena Eilenberg; Adelheid Panzenboeck; Max-Paul Winter; Helga Bergmeister; Rebecca Herzog; Julia Mascherbauer; Irene Lang; Diana Bonderman

Alterations in the nitric oxide (NO) pathway play a major role in pulmonary arterial hypertension (PAH). L-arginine (LA) and tetrahydrobiopterin (BH4) are main substrates in the production of NO, which mediates pulmonary vasodilation. Administration of either LA or BH4 decrease pulmonary artery pressure (PAP). A combined administration of both may have synergistic effects in the therapy of PAH. In a telemetrically monitored model of unilateral pneumonectomy and monocrotaline-induced PAH, male Sprague-Dawley rats received either LA (300 mg/kg; n = 15), BH4 (20 mg/kg; n = 15), the combination of LA and BH4 (300 mg/kg, 20 mg/kg; n = 15), or vehicle (control group; n = 10) from day 28 after monocrotaline induction. Therapy was orally administered once daily over consecutive 14 days. LA, BH4, or both equally lowered PAP, increased pulmonary vascular elasticity, restored spontaneous locomotoric activity, prevented body weight loss and palliated small vessel disease of severely pulmonary hypertensive rats. BH4 substitution lowered asymmetric dimethylarginine levels sustainably at 60 min after administration and downregulated endothelial NO synthase mRNA expression. No significant survival, macro- and histomorphologic or hemodynamic differences were found between therapy groups at the end of the study period. Administration of LA and BH4 both mediated a decrease of mean PAP, attenuated right ventricular hypertrophy and small vessel disease in monocrotaline-induced pulmonary hypertensive rats, though a combined administration of both substances did not reveal any synergistic therapy effects in our animal model.


Critical Care Medicine | 2016

Urinary Output Predicts Survival in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiovascular Surgery.

Klaus Distelmaier; Christian Roth; Christina Binder; Lore Schrutka; Catharina Schreiber; Friedrich Hoffelner; Gottfried Heinz; Irene M. Lang; Gerald Maurer; Herbert Koinig; Barbara Steinlechner; Alexander Niessner; Georg Goliasch

Objectives:Extracorporeal membrane oxygenation represents a valuable and rapidly evolving therapeutic option in patients with severe heart or lung failure following cardiovascular surgery. However, survival remains poor and accurate risk stratification challenging. Therefore, we evaluated the predictive value of urinary output within 24 hours after extracorporeal membrane oxygenation initiation on mortality in patients undergoing venoarterial extracorporeal membrane oxygenation support following cardiovascular surgery and aimed to improve established risk prediction models. Design:Single-center, observational registry. Setting:University-affiliated tertiary care center. Patients:We included 205 patients undergoing veno-arterial extracorporeal membrane oxygenation therapy following cardiovascular surgery at a university-affiliated tertiary-care center into our single-centre registry. Interventions:None. Measurements and Main Results:During a median follow-up time of 35 months (interquartile range, 19–69), 64% of patients died. Twenty-four–hour urinary output was the strongest predictor of outcome among renal function variables with an adjusted hazard ratio per 1 SD of 0.55 (95% CI, 0.40–0.76; p < 0.001) for 30-day mortality and of 0.65 (95% CI, 0.53–0.86; p = 0.002) for 2-year long-term mortality. Most remarkably, 24-hour urinary output showed additional prognostic value beyond that achievable with the simplified acute physiology score-3 and sequential organ failure assessment score indicated by improvements in the category-free net reclassification index for 30-day mortality (simplified acute physiology score-3: 36%, p = 0.015; sequential organ failure assessment score: 36%, p = 0.02), as well as for 2-year mortality (simplified acute physiology score-3: 33%, p = 0.02; sequential organ failure assessment score: 43%, p = 0.005). Conclusions:We identified 24-hour urinary output as a strong and easily available predictor of mortality in patients undergoing extracorporeal membrane oxygenation therapy following cardiovascular surgery. Implementation of 24-hour urinary output leads to a substantial improvement of established risk prediction models in this vulnerable patient population. These results are particularly compelling because measurement of urinary output is inexpensive and routinely performed in all critical care units.


American Journal of Physiology-lung Cellular and Molecular Physiology | 2013

Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model

Magdalena Strobl; Catharina Schreiber; Adelheid Panzenböck; Max-Paul Winter; Helga Bergmeister; Johannes Jakowitsch; Julia Mascherbauer; Irene M. Lang; Paul Wexberg; Diana Bonderman

The use of fractional exhaled nitric oxide (FeNO) has been suggested as a quantitative marker for pulmonary arterial hypertension (PAH) in humans. To further characterize FeNO in PAH we investigated this marker in a rodent model. Since there is no standardized technique for FeNO measurement in animals, we intended to reduce measuring errors and confounders of an existing published method by mathematical modification and tested its applicability in an NO-regulating therapy concept of PAH. Thirty-three male Sprague-Dawley rats underwent unilateral pneumonectomy and monocrotaline (MCT) injection and were observed for 49 days. A telemetric catheter was introduced into the left pulmonary artery to continuously record mean pulmonary arterial pressure (mPAP), and FeNO was assessed. After 35 days, animals were randomized to receive either oral l-arginine (300 mg/kg) in combination with tetrahydrobiopterin (20 mg/kg) therapy (n = 12) or vehicle (n = 11) daily over a period of 14 days. mPAP at baseline was 17.19 ± 9.62 mmHg, which increased to 53.1 ± 10.63 mmHg 28 days after monocrotaline exposure (P < 0.001). Using the modified technique, we found an inverse correlation between exhaled NO and pulmonary pressures before (r = -0.366, P = 0.043) and after MCT (r = -0.363, P = 0.038) as well as after therapy administration (r = -0.657, P = 0.02). Our modified technique proved robust in a rodent model, since valid and reproducible data were gained and showed an inverse correlation between exhaled NO and mPAP, whereas the existing method did not.


European Journal of Clinical Investigation | 2014

Myocardial infarct size measurement using geometric angle calculation

Michael Lichtenauer; Catharina Schreiber; Christian Jung; Lucian Beer; Andreas Mangold; Mariann Gyöngyösi; Bruno K. Podesser; Hendrik Jan Ankersmit

In basic cardiovascular research focusing on animal models of myocardial infarction (MI), the measurement of infarct size is performed by planimetry of histological sections of the heart. However, in the setting of chronic MI with ongoing changes in ventricular geometry caused by wall thinning and hypertrophy, the scar area tends to become smaller.


Journal of the American College of Cardiology | 2013

EXTENT OF DIFFUSE MYOCARDIAL FIBROSIS DETERMINES OUTCOME IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION

Julia Mascherbauer; Beatrice A. Marzluf; Caroline Tufaro; Stefan Pfaffenberger; Alexandra Grad; Catharina Schreiber; Gültekin Karakus; Martin Hülsman; Richard Pacher; Irene M. Lang; Gerald Maurer; Diana Bonderman

The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial fibrosis is believed to play a major role. Our aims were to use cardiac magnetic resonance (CMR) T1 mapping to quantify diffuse myocardial fibrosis, and to identify


Clinical Laboratory | 2017

Impact of Moderate Altitude on Pro-Inflammatory Cytokines in Healthy Volunteers

Christoph Edlinger; Catharina Schreiber; Bjoern Goebel; Rudin Pistulli; Vera Paar; Christiana Schernthaner; Ilonka Rohm; Hans-Reiner Figulla; Uta C. Hoppe; Marcus Franz; Christian Jung; Michael Lichtenauer

BACKGROUND The induction of microvascular inflammation and the effects on cytokine production in blood due to hypoxia has been shown in the past. We have previously reported a statistically significant increase of the pro-inflammatory cytokine interleukin-8 (IL-8) in normobaric hypoxia in the setting of a hypoxia-chamber. In the present study, we sought to analyze plasma levels of inflammatory cytokines in a real-life stetting in order to foster our knowledge on hypoxia induced microvascular inflammation at moderate altitude. METHODS Pro-inflammatory cytokines (IL-8, IL-6, TNF-α) were measured in an experimental field study, exposing 18 healthy volunteers to moderate hypoxia while staying at a mountain lodge in Diavolezza, Switzerland (2978 meters above sea level). Plasma cytokine levels were measured by ELISA. RESULTS In contradiction to our results in a normobaric hypoxia-chamber, exposure to moderate hypoxia led to a significant decrease of plasma IL-8 levels in a real-life setting (from 2.902 (1.046 - 4.984) pg/mL to 1.395 (0.698 - 3.712) pg/mL, p = 0.034). Concentrations of IL-6 and TNF-α did not show statistically significant changes in comparison to baseline measurements. CONCLUSIONS The results of this study show a decrease of proinflammatory cytokine IL-8 in a real life setting of moderate altitude in healthy individuals. Initiation of angiogenesis or subliminal stimulus for an altitude-induced inflammatory reaction may be explanations for this unexpected finding.

Collaboration


Dive into the Catharina Schreiber's collaboration.

Top Co-Authors

Avatar

Helga Bergmeister

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Diana Bonderman

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Irene M. Lang

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Julia Mascherbauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Christian Grasl

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Heinrich Schima

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Ingrid Walter

University of Veterinary Medicine Vienna

View shared research outputs
Top Co-Authors

Avatar

Magdalena Strobl

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Gerald Maurer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Martin Stoiber

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge